BMY
Healthcare
Bristol-Myers Squibb: The Forensic Case That The Patent Cliff Math Has Already Been Solved
BMY trades at 9.3x P/E and a 4.5% yield while three forensic mispricings sit in plain sight: the Eliquis IRA cliff that didn't happen, a growth/legacy crossover already cleared in 2025, and a $14B Cobenfy option the Street is valuing at zero. Rating: BUY. 12-month target $78, multi-year intrinsic $95+.